Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Non-Current Deffered Revenue (2016 - 2018)

Alaunos Therapeutics (TCRT) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $4000.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deffered Revenue fell 97.18% year-over-year to $4000.0, compared with a TTM value of $4000.0 through Dec 2018, down 97.18%, and an annual FY2018 reading of $4000.0, down 97.18% over the prior year.
  • Non-Current Deffered Revenue was $4000.0 for Q4 2018 at Alaunos Therapeutics, down from $30000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $38.3 million in Q2 2017 and bottomed at $3000.0 in Q1 2018.
  • Average Non-Current Deffered Revenue over 5 years is $2.3 million, with a median of $401000.0 recorded in 2015.
  • The sharpest move saw Non-Current Deffered Revenue soared 8962.17% in 2017, then crashed 99.82% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $570000.0 in 2014, then increased by 15.96% to $661000.0 in 2015, then crashed by 80.94% to $126000.0 in 2016, then grew by 12.7% to $142000.0 in 2017, then plummeted by 97.18% to $4000.0 in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for TCRT at $4000.0 in Q4 2018, $30000.0 in Q3 2018, and $68000.0 in Q2 2018.